NervGen Pharma Reports 2023 Year-End Financial Results and Operational Updates
Anticipated completion of enrollment of the chronic cohort in the Phase 1b/2a clinical trial in Q2 2024 CA$23 million bought deal financing completed in March 2024 provides expected cash runway through Q3 2025 Fast Track designation granted by U.S. Food and Drug Administration (FDA) for NVG-291 in spinal cord injury Vancouver, Canada April 17, […]
NervGen Completes $23 Million Bought Deal Financing
NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. Vancouver, British Columbia March 28, 2024 – NervGen Pharma Corp. (“NervGen” or the “Company”) (TSXV: NGEN) is pleased to announce the closing of its previously announced public offering (the “Offering”) including the full exercise of the underwriters’ over-allotment […]
NervGen Announces $20 Million Bought Deal Offering
NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. Vancouver, British Columbia March 21, 2024 – NervGen Pharma Corp. (“NervGen” or the “Company”) (TSXV: NGEN) is pleased to announce that it has entered into an agreement with a syndicate of underwriters led by Stifel Canada, Canaccord Genuity […]
NervGen Pharma Recognized as a Top 50 TSX Venture Exchange Company
Vancouver, Canada, February 21, 2024 – NervGen Pharma Corp. (TSX-V: NGEN; OTCQX: NGENF), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, has been recognized by the TSX Venture Exchange as a 2023 Top 50 Company. The 2024 TSX Venture 50™ showcases the strongest performances on the TSX […]
NervGen Pharma Grants Stock Options
Vancouver, Canada, February 20, 2024 – NervGen Pharma Corp. (TSX-V: NGEN; OTCQX: NGENF), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, today announced that it has granted incentive stock options to the Company’s employees, including 505,200 to the Company’s Officers exercisable at a price of $3.48 per […]
NervGen Pharma on Track to Complete Enrollment, Deliver Data Readout in Phase 1b/2a Clinical Trial for NVG-291 in Spinal Cord Injury
On track to complete enrollment of the chronic cohort in Q2 2024 Data readout from chronic cohort expected in Q3 2024 Planning underway to make NVG-291 available to placebo-treated subjects following cohort completion Vancouver, Canada, February 15, 2024 – NervGen Pharma Corp. (TSX-V: NGEN; OTCQX: NGENF), a clinical stage biotech company dedicated to developing innovative […]
NervGen Pharma Reports Q3 2023 Financial Results and Operational Updates
Phase 1a/2b clinical trial of NVG-291 underway with dosing of individuals with spinal cord injury; results from chronic cohort expected in mid-2024 Fast Track designation granted by U.S. Food and Drug Administration (FDA) for NVG-291 in spinal cord injury Seasoned financial industry executive, John Ruffolo, appointed to Board Vancouver, Canada. November 9, 2023 – […]
Neuroscientist and NervGen Pharma Scientific Founder, Dr. Jerry Silver, Interviewed on ‘Remarkable People’ Podcast Hosted by Tech Luminary Guy Kawasaki
Dr. Silver’s life work, culminating in NervGen’s NVG-291, is currently in a Phase 1b/2a clinical trial for individuals with spinal cord injury. Vancouver, Canada, November 8, 2023 – NervGen Pharma Corp. (TSX-V: NGEN; OTCQX: NGENF), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, announced today that […]
NervGen Pharma Receives Fast Track Designation for NVG-291 for the Treatment of Individuals with Spinal Cord Injury
– Designation Facilitates and Expedites Development of Drugs for Patients with Serious Unmet Medical Needs – Enrollment Progressing in NVG-291 Phase 1b/2a Clinical Trial, with Initial Cohort Data Expected in Mid-2024 Vancouver, Canada, October 23, 2023 – NervGen Pharma Corp. (TSX-V: NGEN; OTCQX: NGENF), a clinical stage biotech company dedicated to developing innovative solutions for […]
NervGen Pharma Announces First Subject Dosed in Landmark Phase 1b/2a Clinical Trial for NVG-291 in Spinal Cord Injury
Chronic spinal cord injury cohort results expected in mid-2024 Subacute spinal cord injury cohort results expected in late 2024/early 2025 Vancouver, Canada, September 25, 2023 – NervGen Pharma Corp. (TSX-V: NGEN; OTCQX: NGENF), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, today announced the first subject […]
